Redx Pharma

Focus: Redx Pharma is a UK-based small molecule oncology and fibrosis-focused biotech company headquartered in Macclesfield. The company is developing a focused pipeline of targeted therapies across early-to-mid clinical stages.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Redx Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Redx Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

RXC004

Cancer

Phase 1

Clinical Trials (1)

NCT03447470Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

Phase 1

Help build intelligence for Redx Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused oncology and fibrosis pipeline with 4 active clinical programs provides clear therapeutic focus and potential for meaningful contributions to high-priority disease areas
Phase 2 programs in colorectal cancer (RXC004) and IPF (RXC007) represent near-term clinical catalysts that could accelerate company trajectory
Small molecule expertise and UK location offer access to European scientific networks and potentially competitive cost-of-living vs. US biotech hubs

Watch Out For

Zero active job openings reported suggests minimal near-term hiring; company may be in consolidation or pre-fundraising mode
No Phase 3 programs in pipeline indicates 3-5 year minimum to potential regulatory milestone; early-stage risk profile typical of pre-revenue biotech
Complete absence of financial data (revenue, funding, cash runway) prevents assessment of company stability or restructuring risk

Generated by Claude from Redx Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

RXC007

Fibrosis

Phase 1

Clinical Trials (1)

NCT04931147A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers

Phase 1

RXC004

Colorectal Cancer

Phase 2

Clinical Trials (1)

NCT04907539A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

Phase 2

RXC004

Advanced Solid Tumours

Phase 2